Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Jumps 62.8%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 226,620 shares, an increase of 62.8% from the August 31st total of 139,192 shares. Based on an average daily volume of 67,897 shares, the days-to-cover ratio is presently 3.3 days. Approximately 1.4% of the shares of the stock are short sold.

Analyst Ratings Changes

Several brokerages have recently commented on MRKR. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a research note on Friday, August 21st. Weiss Ratings upgraded shares of Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned about 0.41% of Marker Therapeutics at the end of the most recent reporting period. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Trading Down 1.9%

NASDAQ:MRKR opened at $1.05 on Friday. Marker Therapeutics has a 52 week low of $0.84 and a 52 week high of $2.46. The firm has a market capitalization of $17.50 million, a PE ratio of -2.56 and a beta of 1.53. The stock has a 50 day moving average of $1.21 and a 200-day moving average of $1.35.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. As a group, analysts predict that Marker Therapeutics will post -0.64 EPS for the current fiscal year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc (NASDAQ: MRKR) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s approach uses multiTAA-specific T cells, which are designed to recognize and attack multiple tumor-associated antigens rather than a single target. Marker Therapeutics is developing these therapies for patients with solid tumors and certain hematologic malignancies.

The company’s lead investigational product, MT-601, is an autologous multiTAA-specific T-cell therapy being evaluated in clinical development, including for pancreatic cancer.